GLP1_NEW
ECC5004 30 mg tablet once daily
ECC500_PO_30MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.72 (0.01 to 60.80) | 0.53 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.86 (1.61 to 45.93) | 0.18 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.71 (0.16 to 70.02) | 0.42 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.94 (0.13 to 5.17) | 0.67 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 5.03 (1.36 to 22.24) | 0.15 |